OncoMatch/Clinical Trials/NCT05167994

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）

Is NCT05167994 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Anlotinib hydrochloride for sarcoma,soft tissue.

Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05167994Data as of May 2026

Treatment: Anlotinib hydrochloride — To investigate the safety and efficacy of preoperative IMRT and concurrent Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination treatment; To study the mechanism of radio-sensitizing effects of Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and local control.

Check if I qualify

Extracted eligibility criteria

Cancer type

Sarcoma

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

Cannot have received: radiation therapy

Cannot have received: neoadjuvant chemotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify